Eflornithine is an agent that can be used to treat glioma, especially glioma of WHO Grade II or Grade III such as anaplastic glioma. Eflornithine can suppress or prevent mutations in glioma which can cause the glioma to progress to a higher grade. Compositions and methods can include eflornithine or a derivative or analog of eflornithine, together with other agents such as conventional anti-neoplastic agents for treatment of glioma, inhibitors of polyamine transport, polyamine analogs, or S-adenosylmethionine decarboxylase inhibitors.

A method of selectively targeting a cell with a therapeutic agent, the method comprising: targeting a cell with a nanospear, puncturing the cell with said nanospear; releasing a therapeutic agent from said nanospear, wherein said therapeutic agent enters said cell, thereby effecting the efficacy of said cell.

Methods for treating cancer using compounds that inhibit human DNA ligases. Methods for using compounds that inhibit human DNA ligases to provide insights into the reaction mechanisms of human DNA ligases, for example to identify the human DNA ligase involved in different DNA repair pathways. Screening methods for compounds that inhibit human DNA ligases.

Methods for treating cancer using compounds that inhibit human DNA ligases. Methods for using compounds that inhibit human DNA ligases to provide insights into the reaction mechanisms of human DNA ligases, for example to identify the human DNA ligase involved in different DNA repair pathways. Screening methods for compounds that inhibit human DNA ligases.

The invention relates to new cancer treatment strategies based on the inhibition of acid lipase. In addition, the invention relates to methods for discovering new active substances suitable for cancer therapy.

The invention relates to new cancer treatment strategies based on the inhibition of acid lipase. In addition, the invention relates to methods for discovering new active substances suitable for cancer therapy.

A combination of antitumor agents significantly shrinks tumors by synergistic antitumor action without increasing side effects to the extent possible. The antitumor composition contains compound (B) or a salt thereof for use in combination with antitumor agent (A), where (A) is at least one antitumor agent selected from alkylating agents, CD20 recognition molecules, DNA methylation inhibitors, pyrimidine antimetabolites, purine antimetabolites, antifolates, Bcl-2 inhibitors, and tyrosine kinase inhibitors; and (B) is a compound or a salt thereof represented by formula (1):

##STR00001##

where R.sup.1 is halogen, aryl, aryloxy, or lower alkyl optionally substituted with one or more halogen atoms; R.sup.2 is hydrogen, halogen, lower alkyl, or lower alkoxy; and m=1 to 3, provided that when m is 2 or 3, each R.sup.1 is the same or different.

A combination of antitumor agents significantly shrinks tumors by synergistic antitumor action without increasing side effects to the extent possible. The antitumor composition contains compound (B) or a salt thereof for use in combination with antitumor agent (A), where (A) is at least one antitumor agent selected from alkylating agents, CD20 recognition molecules, DNA methylation inhibitors, pyrimidine antimetabolites, purine antimetabolites, antifolates, Bcl-2 inhibitors, and tyrosine kinase inhibitors; and (B) is a compound or a salt thereof represented by formula (1):

##STR00001##

where R.sup.1 is halogen, aryl, aryloxy, or lower alkyl optionally substituted with one or more halogen atoms; R.sup.2 is hydrogen, halogen, lower alkyl, or lower alkoxy; and m=1 to 3, provided that when m is 2 or 3, each R.sup.1 is the same or different.

The present disclosure features useful methods to treat an ALT-positive cancer and/or a cancer having a deficiency in ATRX and/or DAXX, e.g., in a subject in need thereof. In some embodiments, the methods described herein are useful in the treatment of cancer in combination with anti-cancer therapies.

The present disclosure features useful methods to treat an ALT-positive cancer and/or a cancer having a deficiency in ATRX and/or DAXX, e.g., in a subject in need thereof. In some embodiments, the methods described herein are useful in the treatment of cancer in combination with anti-cancer therapies.